Israeli Channel 2 TV interviewed a patient suffering from Myasthenia Gravis (MG) and recently diagnosed with ALS. The patient reported that he has experienced visible improvement in his speech, walking, balance, posture, muscle strength, appetite, digestion, and weight gain following compassionate treatment with BrainStorm’s NurOwn cell therapy. “Due to the...
Read more
Category Archives: Articles
Bonus Biogroup Raises NIS 4 M for Bone Regeneration
Bone regeneration company Bonus Biogroup Ltd. (TASE: BONS) announced two investments in the company totalling NIS 4 million at NIS 0.48 per share. Bonus Biogroup’s share price has more than tripled so far in June. Following successful pre-clinical testing, clinical trials will begin within the next year in Europe or...
Read more
Orphan Drug Status for Medgenics Biopump
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) has received Orphan Drug Designation from the FDA for the treatment of hepatitis D using its Biopump technology. INFRADURE is the version of Medgenics’ Biopump technology platform which produces interferon alpha, commonly used to treat hepatitis. This marks the first Orphan...
Read more
BioLight Expands Opthalmic Cluster
BioLight is expanding its ophtalmic cluster, by adding an ocular impant to its portfolio. The company signed a non-binding Memorandum of Understanding with an American company, Butter recycling Amazon new healthy man reviews enough budge hairspray pfizer viagra This in, sink pharmacy express canada cincinnatimontessorisociety.org applying bleached… Hair and order...
Read more
BrainStorm Promotes Adrian Harel to Permanent CEO
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) announced that it has received the first installment of the 2012 grant from Israel’s Office of the Chief Scientist (OCS) in the amount ofapproximately $350,000. The yearly grant for 2012 is $ 1,100,000 (~4.2 M NIS). The grant is awarded to BrainStorm’s Research and...
Read more
Medicare to Cover Rosetta Genomics Cancer Diagnostic
Rosetta Genomics Ltd. (NASDAQ: ROSG)announced that Novitas, the designated Medicare Administrative Contractor for the Company’s miRview(R) mets^2 assay, has informed Rosetta that it plans to cover this assay for all Medicare beneficiaries. MiRview(R) mets^2 accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown...
Read more
RedHill Migraine Trial Successful
RedHill Biopharma Ltd. (TASE: RDHL) announced positive results in a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of Rizatriptan for the treatment of acute migraine. RedHill has exclusive world-wide rights and is developing RHB-103 with its Canadian co-development partner IntelGenx, Corp. (TSX: IGX ; OTCBB: IGXT). Analysis...
Read more
GE Healthcare Invests $27.5 M in Insightec
Elbit Medical Technologies Ltd. (TASE: EMTC) announced that its subsidiary InSightec Image Guided Treatment Ltd. has signed a memorandum of understanding with GE Healthcare. Under the agreement, GE Healthcare will invest $27.5 million in the company. Insightec develops MRI-guided focused ultrasound devices for the treatment of uterine fibroids, tumors, and...
Read more
CollPlant Wound Trial Interim Results
CollPlant Holdings Ltd. (TASE: CLPT) reported successful interim results in a preclinical (animal) trial its VergenixFG wound dressing gel made of pure recombinant human collagen, for the treatment of skin lesions. The trial found that the product was effective and had statistically significant better results than corresponding products on the...
Read more
BrainStorm to do MS Stem Cell Study
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) plans to initiate a preclinical study assessing the efficacy of its NurOwn™ stem cell technology in patients with Multiple Sclerosis (MS). Positive proof-of-concept results for MS have been confirmed in a set of in-vitro and in-vivo experiments, and the Company is working to advance...
Read more
Rosetta Genomics Gets Cancer Diagnostic Patent
Rosetta Genomics, Ltd. (NASDAQ: ROSG) has received a patent allowance from the U.S. Patent and Trademark Office (“USPTO”) for Patent Application 12/800,556 titled, “MICRORNAS AND USES THEREOF.” The allowed claims cover the composition of matter for miR-378, a core element of Rosetta Genomics’ microRNA technology used in its miRview(R) mets...
Read more
Brainsway: Positive Depression Trial Results
Brainsway Ltd. (TASE:BRIN) announced positive results from its double-blind multicenter clinical trial for the assessment of the safety and efficacy of Deep Transcranial Magnetic Stimulation (“Deep TMS”) with the Company’s device (the “H-Coil”) in the treatment of major depression. Based on a U.S. Food and Drug Administration (“FDA”) approved clinical...
Read more
InspireMD Completing Stent Trial
InspireMD, Inc. (OTC BB: NSPR) announced that the 313th patient has been enrolled in the MASTER (MGuard™ for Acute ST Elevation Reperfusion) trial. The trial is scheduled to enroll 432 patients in total and the Company is on track to release preliminary top line results in the third quarter of...
Read more
Protalix Gets FDA Approval
Pfizer Inc.(NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX) announced that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO(TM) (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease. ELELYSO is the first FDA-approved...
Read more
D-Pharm Gets $1M from Chinese Partner
D-Pharm Ltd., (TASE: DPRM) has received the first payment of $1M from Jiangsu NHWA Pharmaceutical Co., Ltd. (NHWA) in relation to DP-VPA development for epilepsy in China. NHWA is the leading Chinese company developing and marketing drugs to treat CNS disorders in China. DP-VPA is a novel drug discovered and...
Read more
cCam Raises $3 M
cCam Medical Ltd. has raised $3 million from Pontifax Ltd. and Mori Arkin’s Arkin Holdings Ltd. $2.5 million will be transferred at the signing and the balance in milestone payments. cCam also extended its cooperation agreement with Hoffmann-La Roche, which has the right to commercialize the company’s technology in exchange...
Read more
Pluristem Phase II Uses Placenta-Based Therapy
Pluristem Therapeutics, Inc. (NasdaqCM: PSTI; TASE: PLTR), has been granted clearance from the FDA to start a Phase II clinical trial using the company’s PLX-PAD cell product candidate for the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). Pluristem’s IC Phase II trial will evaluate the...
Read more
BioLert Links with My Epilepsy Diary
BioLert has linked the Epilert model V1 to the internet by developing software that interfaces with My Epilepsy Diary™, a service provided by the Epilepsy Therapy Project and Irody. http://www.epilepsy.com/epilepsy_therapy_project BioLert is the developer of the wearable Epilert Seizure Alert Device that automatically alerts families and caregivers of a patient...
Read more
Prolor: Positive Obesity/Diabetes Study
PROLOR Biotech, Inc. (NYSE Amex: PBTH) reported positive preclinical results from an animal study of its long-acting obesity/Type II diabetes drug candidate MOD-6030. The study was designed to measure the potential therapeutic effect of MOD-6030 injected once weekly as measured by weight loss, reduction in food intake, glycemic control and...
Read more
Can-Fite: Ophthalix Drug Effective for Eye Disease
OphthaliX (OTCBB: OPLI) has completed preclinical studies showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis. The pre-clinical study data demonstrated that CF101 is efficacious in preventing the clinical manifestations of Anterior Uveitis in a well-established animal model. The current study data together with the previous published...
Read more